Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease.

Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease.

Budge Kevin M; Neal Matthew L; Richardson Jason R; Safadi Fayez F

Molecular neurobiology

2018

2018-06

Neurodegeneration is characterized by severe neuronal loss leading to the cognitive and physical impairments that define various neurodegenerative diseases. Neuroinflammation is one hallmark of neurodegenerative diseases and can ultimately contribute to disease progression. Increased inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1beta (IL-1 beta), and tumor necrosis factor-alpha (TNF-alpha) are associated with Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Unfortunately, current therapeutic options lack ability to stop or effectively slow progression of these diseases and are primarily aimed at alleviating symptoms. Thus, it is crucial to discover novel treatment candidates for neurodegenerative diseases. Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a type-I transmembrane glycoprotein first identified in a melanoma cell line. GPNMB augments bone mineral deposition by stimulating osteoblast differentiation. Aside from its anabolic function in the bone, emerging evidence suggests that GPNMB has anti-inflammatory and reparative functions. GPNMB has also been demonstrated to be neuroprotective in an animal model of ALS, cerebral ischemia, and other disease models. Given these discoveries, GPNMB should be investigated as a potential therapeutic option for multiple neurodegenerative diseases.

Animals; GPNMB; Humans; Immune System/metabolism; Membrane Glycoproteins/chemistry/*metabolism; Nerve Degeneration/pathology; Neurodegeneration; Neurodegenerative Diseases/*metabolism/therapy; Neuroinflammation; Neuroprotection

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

5167–5176

6

55